Literature DB >> 28565864

Expression of Krüppel-like factor 4 in breast cancer tissues and its effects on the proliferation of breast cancer MDA-MB-231 cells.

Xiang Song1, Yue-Ming Xing1, Wei Wu1, Guo-Hua Cheng1, Feng Xiao1, Gang Jin1, Ying Liu1, Xin Zhao1.   

Abstract

The aim of the present study was to detect the expression of Krüppel-like factor 4 (KLF4) in breast cancer tissues and to evaluate the effect on the proliferation of breast cancer MDA-MB-231 cells. The expression of KLF4 protein in 239 breast cancer tissues and 40 paracancerous tissues were detected by an immunohistochemical assay, and its correlation with clinical pathological parameters was analyzed. A eukaryotic expression vector, pcDNA3.1-KLF4, was constructed by transient transfection of breast cancer MDA-MB-231 cells with liposomes (experimental group). The untransfected cells and those transfected with empty plasmid pcDNA3.1 were used as the blank and negative control groups, respectively. The expression of the KLF4 gene and protein in the three groups were detected by reverse transcription polymerase chain reaction and western blotting, respectively. Furthermore, the cell proliferative capacity was detected by an MTT assay. The positive expression rate of KLF4 protein in breast cancer tissues (39.0%, 93/239) was significantly lower than that of paracancerous tissues (77.5%, 31/40) (P<0.05). In addition, KLF4 protein expression in breast cancer tissues was correlated with pathological type, histological grade and lymphatic metastasis (P<0.05). KLF4 mRNA and protein were both expressed by the experimental group, but not by the two control groups. Meanwhile, the proliferative capacity of the experimental group was also significantly decreased. A significant decrease in the positive expression rate of KLF4 protein in breast cancer tissues was correlated with several clinical pathological parameters. In addition, transfection of the KLF4 gene inhibited the proliferation of breast cancer cells, suggesting that this gene is important in the onset and progression of this type of cancer.

Entities:  

Keywords:  Krüppel-like factor 4; breast cancer; cell proliferation

Year:  2017        PMID: 28565864      PMCID: PMC5443194          DOI: 10.3892/etm.2017.4262

Source DB:  PubMed          Journal:  Exp Ther Med        ISSN: 1792-0981            Impact factor:   2.447


  30 in total

1.  Krüppel-like factor 4 inhibits tumorigenic progression and metastasis in a mouse model of breast cancer.

Authors:  Jennifer L Yori; Darcie D Seachrist; Emhonta Johnson; Kristen L Lozada; Fadi W Abdul-Karim; Lewis A Chodosh; William P Schiemann; Ruth A Keri
Journal:  Neoplasia       Date:  2011-07       Impact factor: 5.715

2.  Characterization of the structure and regulation of the murine gene encoding gut-enriched Krüppel-like factor (Krüppel-like factor 4).

Authors:  C S Mahatan; K H Kaestner; D E Geiman; V W Yang
Journal:  Nucleic Acids Res       Date:  1999-12-01       Impact factor: 16.971

Review 3.  The descriptive epidemiology of female breast cancer: an international comparison of screening, incidence, survival and mortality.

Authors:  Danny R Youlden; Susanna M Cramb; Nathan A M Dunn; Jennifer M Muller; Christopher M Pyke; Peter D Baade
Journal:  Cancer Epidemiol       Date:  2012-03-27       Impact factor: 2.984

4.  Persistent Krüppel-like factor 4 expression predicts progression and poor prognosis of head and neck squamous cell carcinoma.

Authors:  Shyh-Kuan Tai; Muh-Hwa Yang; Shyue-Yih Chang; Yung-Chi Chang; Wing-Yin Li; Tung-Lung Tsai; Yi-Fen Wang; Pen-Yuan Chu; Shie-Liang Hsieh
Journal:  Cancer Sci       Date:  2011-03-04       Impact factor: 6.716

5.  Induction of KLF4 in basal keratinocytes blocks the proliferation-differentiation switch and initiates squamous epithelial dysplasia.

Authors:  K Wade Foster; Zhaoli Liu; Clinton D Nail; Xingnan Li; Thomas J Fitzgerald; Sarah K Bailey; Andra R Frost; Iuri D Louro; Tim M Townes; Andrew J Paterson; Jeffrey E Kudlow; Susan M Lobo-Ruppert; J Michael Ruppert
Journal:  Oncogene       Date:  2005-02-24       Impact factor: 9.867

6.  Report of incidence and mortality in china cancer registries, 2008.

Authors:  Wan-Qing Chen; Rong-Shou Zheng; Si-Wei Zhang; Ni Li; Ping Zhao; Guang-Lin Li; Liang-You Wu; Jie He
Journal:  Chin J Cancer Res       Date:  2012-09       Impact factor: 5.087

7.  Putative tumor-suppressive function of Kruppel-like factor 4 in primary lung carcinoma.

Authors:  Wenxian Hu; Wayne L Hofstetter; Hong Li; Yanbin Zhou; Yong He; Abujiang Pataer; Li Wang; Keping Xie; Stephen G Swisher; Bingliang Fang
Journal:  Clin Cancer Res       Date:  2009-09-08       Impact factor: 12.531

Review 8.  Roles of Krüpel-like factor 4 in normal homeostasis, cancer and stem cells.

Authors:  Paul M Evans; Chunming Liu
Journal:  Acta Biochim Biophys Sin (Shanghai)       Date:  2008-07       Impact factor: 3.848

9.  Nuclear Krüppel-like factor 4 expression is associated with human skin squamous cell carcinoma progression and metastasis.

Authors:  Yi-Ju Chen; Chun-Ying Wu; Chia-Che Chang; Chieh-Ju Ma; Mu-Chun Li; Chuan-Mu Chen
Journal:  Cancer Biol Ther       Date:  2008-05-20       Impact factor: 4.742

10.  Epigenetic alterations of Krüppel-like factor 4 and its tumor suppressor function in renal cell carcinoma.

Authors:  Heng Li; Ji Wang; Wei Xiao; Ding Xia; Bin Lang; Gan Yu; Xiaolin Guo; Wei Guan; Zhihua Wang; Zhiquan Hu; Jihong Liu; Zhangqun Ye; Hua Xu
Journal:  Carcinogenesis       Date:  2013-05-30       Impact factor: 4.944

View more
  3 in total

1.  Cyanidin-3-O-glucoside inhibits epithelial-to-mesenchymal transition, and migration and invasion of breast cancer cells by upregulating KLF4.

Authors:  Dahu Chen; Mei Yuan; Qin Ye; Xing Wang; Jing Xu; Guangyi Shi; Zhaodi Hu
Journal:  Food Nutr Res       Date:  2020-09-28       Impact factor: 3.894

Review 2.  Breast cancer stem cells: A review of their characteristics and the agents that affect them.

Authors:  Naing L Shan; Yoosub Shin; Ge Yang; Philip Furmanski; Nanjoo Suh
Journal:  Mol Carcinog       Date:  2021-01-11       Impact factor: 4.784

3.  KLF4 defines the efficacy of the epidermal growth factor receptor inhibitor, erlotinib, in triple-negative breast cancer cells by repressing the EGFR gene.

Authors:  Melyssa S Roberts; Lindsey J Anstine; Viviane S Finke; Benjamin L Bryson; Bryan M Webb; Kristen L Weber-Bonk; Darcie D Seachrist; Parth R Majmudar; Ruth A Keri
Journal:  Breast Cancer Res       Date:  2020-06-18       Impact factor: 6.466

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.